| TAVR | SAVR |
Inception | 2011 (in the U.S.) | 1960 |
Eligible Population (STS-PROM Score) | High risk (>8%), intermediate risk (4% - 8%), low risk (<4%) | Intermediate risk (4% - 8%), low risk (<4%), younger patients *1/3 of patients not eligible |
Procedure | Minimally invasive procedure | Requires full sternotomy or less invasive mini-sternotomy, cardiopulmonary bypass, cross-clamping of the aorta |
| Bioprosthetic valve is placed directly over the damaged native valve | Native stenotic valve is removed |
| Small vascular punctures (transfemoral) | Large surgical incision |
| Conscious sedation with local anesthesia (transfemoral) | General anesthesia with intubation |
Procedural Setting | Cardiac catheterization lab | Operating room |
Average Procedure Duration | 84 mins | 236 mins |
Average Length of Stay | 4.6 days | 10.9 days |
Valve Cost | $32,000 | $5,000 |
Average Total Admission Costs (including procedure) | $54,256 | $58,410 |
Average 1-Year Cumulative Costs | $80,977 | $96,489 |
2-Year Mortality | 13.1% | 17.1% |